The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity
Open accessAbstract
Anticancer vaccines train the body's own immune system to recognize and eliminate malignant cells based on differential antigen expression. While conceptually attractive, clinical efficacy is lacking given several key challenges stemming from the similarities between cancerous and healthy tissue. Ideally, an effective vaccine formulation would deliver multiple tumor antigens in a fashion that potently stimulates endogenous immune responses against those antigens. Here, it is reported on the fabrication of a biomimetic, nanoparticulate anticancer vaccine that is capable of delivering autologously derived tumor antigen material together with a highly immunostimulatory adjuvant. The two major components, tumor antigens and adjuvant, are presented concurrently in a fashion that maximizes their ability to promote effective antigen presentation and activation of downstream immune processes. Ultimately, it is demonstrated that the formulation can elicit potent antitumor immune responses in vivo. When combined with additional immunotherapies such as checkpoint blockades, the nanovaccine demonstrates substantial therapeutic effect. Overall, the work represents the rational application of nanotechnology for immunoengineering and can provide a blueprint for the future development of personalized, autologous anticancer vaccines with broad applicability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
Hu, C.-M. J., Zhang, L., Aryal, S., Cheung, C., Fang, R. H., & Zhang, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106634108 · Cited by 2,433
Self-citationImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cited by
Cell Membrane Coating Nanotechnology
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885
Self-citationTargeting drugs to tumours using cell membrane-coated nanoparticles
Fang, R. H., Gao, W., & Zhang, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00699-x · Cited by 980
Self-citationRecent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818
Yang, R., Xu, J., Xu, L., Sun, X., Chen, Q., Zhao, Y., Peng, R., & Liu, Z. (2018) · ACS Nano · doi:10.1021/acsnano.7b09041 · Cited by 698
Liu, C., Wang, D., Zhang, S., Cheng, Y., Yang, F., Xing, Y., Xu, T., Dong, H., & Zhang, X. (2019) · ACS Nano · doi:10.1021/acsnano.8b09387 · Cited by 641
Unlocking the promise of mRNA therapeutics
Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01491-z · Cited by 612
Xu, J., Lv, J., Zhuang, Q., Yang, Z., Cao, Z., Xu, L., Pei, P., Wang, C., Wu, H., Dong, Z., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-00781-4 · Cited by 561
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Cell Membrane Coating Technology: A Promising Strategy for Biomedical Applications
Liu, Y., Luo, J., Chen, X., Liu, W., & Chen, T. (2019) · Nano-Micro Letters · doi:10.1007/s40820-019-0330-9 · Cited by 408
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Sang, W., Zhang, Z., Dai, Y., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 405
Recent progress in targeted delivery vectors based on biomimetic nanoparticles
Chen, L., Hong, W., Ren, W., Xu, T., Qian, Z., & He, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00631-2 · Cited by 374
Jiang, Y., Krishnan, N., Zhou, J., Chekuri, S., Wei, X., Kroll, A. V., Yu, C. L., Duan, Y., Gao, W., Fang, R. H., et al. (2020) · Advanced Materials · doi:10.1002/adma.202001808 · Cited by 371
Self-citationEngineering Magnetosomes for Ferroptosis/Immunomodulation Synergism in Cancer
Zhang, F., Li, F., Lu, G.-H., Nie, W., Zhang, L., Lv, Y., Bao, W., Gao, X., Wei, W., Pu, K., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b00892 · Cited by 357
Self-citationLigand-Modified Cell Membrane Enables the Targeted Delivery of Drug Nanocrystals to Glioma
Chai, Z., Ran, D., Lu, L., Zhan, C., Ruan, H., Hu, X., Xie, C., Jiang, K., Li, J., Zhou, J., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b00661 · Cited by 356
Self-citationChen, L., Zhou, L., Wang, C., Han, Y., Lu, Y., Liu, J., Hu, X., Yao, T., Lin, Y., Liang, S., et al. (2019) · Advanced Materials · doi:10.1002/adma.201904997 · Cited by 337
Biomimetic Nanotechnology toward Personalized Vaccines
Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2020) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 328
Self-citationRecent Advances in Glucose‐Oxidase‐Based Nanocomposites for Tumor Therapy
Wang, M., Wang, D., Chen, Q., Li, C., Li, Z., & Lin, J. (2019) · Small · doi:10.1002/smll.201903895 · Cited by 302
Cell membrane biomimetic nanoparticles for inflammation and cancer targeting in drug delivery
Wang, H., Liu, Y., He, R., Xu, D., Zang, J., Weeranoppanant, N., Dong, H., & Li, Y. (2020) · Biomaterials Science · doi:10.1039/c9bm01392j · Cited by 297
Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic
Wu, H.-H., Zhou, Y., Tabata, Y., & Gao, J.-Q. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.019 · Cited by 288
Self-citationCancer Cell Membrane-Coated Nanoparticles for Cancer Management
Harris, J. C., Scully, M. A., & Day, E. S. (2019) · Cancers · doi:10.3390/cancers11121836 · Cited by 278
Liu, W.-L., Zou, M.-Z., Liu, T., Zeng, J.-Y., Li, X., Yu, W.-Y., Li, C.-X., Ye, J.-J., Song, W., Feng, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11157-1 · Cited by 272
Artificial Enzyme Catalyzed Cascade Reactions: Antitumor Immunotherapy Reinforced by NIR‐II Light
Wen, M., Ouyang, J., Wei, C., Li, H., Chen, W., & Liu, Y. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201909729 · Cited by 269
Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy
Ling, X., Tu, J., Wang, J., Shajii, A., Kong, N., Feng, C., Zhang, Y., Yu, M., Xie, T., Bharwani, Z., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06400 · Cited by 263
Programming cell pyroptosis with biomimetic nanoparticles for solid tumor immunotherapy
Zhao, P., Wang, M., Chen, M., Chen, Z., Peng, X., Zhou, F., Song, J., & Qu, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120142 · Cited by 263
Cell membrane coated-nanoparticles for cancer immunotherapy
Zeng, Y., Li, S., Zhang, S., Wang, L., Yuan, H., & Hu, F. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.023 · Cited by 238
Phototheranostics: Active Targeting of Orthotopic Glioma Using Biomimetic Proteolipid Nanoparticles
Jia, Y., Wang, X., Hu, D., Wang, P., Liu, Q., Zhang, X., Jiang, J., Liu, X., Sheng, Z., Liu, B., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06556 · Cited by 211
Cell membrane-derived vesicles for delivery of therapeutic agents
Le, Q.-V., Lee, J., Lee, H., Shim, G., & Oh, Y.-K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.020 · Cited by 181
Wang, J., Zhu, M., & Nie, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113974 · Cited by 153
Tiwari, P., Yadav, K., Shukla, R. P., Gautam, S., Marwaha, D., Sharma, M., & Mishra, P. R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.016 · Cited by 88
Current progress of mesenchymal stem cell membrane-camouflaged nanoparticles for targeted therapy
Fan, L., Wei, A., Gao, Z., & Mu, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114451 · Cited by 57
Jian, C., Wu, T., Wang, L., Gao, C., Fu, Z., Zhang, Q., & Shi, C. (2024) · Small · doi:10.1002/smll.202309279 · Cited by 33
Metadata
- Authors
- Kroll, A. V., Fang, R. H., Jiang, Y., Zhou, J., Wei, X., Yu, C. L., Gao, J., Luk, B. T., Dehaini, D., Gao, W., & Zhang, L.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2017-11-02
- Volume
- 29
- Issue
- 47
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2765097474
- Cited by
- 501
- References
- 49
- FWCI
- 15.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.